Dupilumab improves alcohol tolerance in aspirin-exacerbated respiratory disease

Abstract

Aspirin-exacerbated respiratory disease (AERD) presents with a triad of nasal polyps, asthma, and aspirin and nonsteroidal anti-inflammatory drug sensitivity. It is characterized by often recalcitrant type 2 inflammation with dysregulated arachidonic acid metabolism, mast cell activation, and blood and airway eosinophilia.1 In addition to characteristic respiratory reactions with cyclooxygenase-1 (COX-1) inhibitors, patients with AERD often have alcohol sensitivity. Up to 75% of patients with AERD have upper airway symptoms (sneezing, rhinorrhea, nasal congestion) whereas 51% have lower respiratory symptoms (wheezing, dyspnea)2 that are not specific to the type or amount of alcohol ingested.